دورية أكاديمية
أعرض في EDS

Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.

التفاصيل البيبلوغرافية
العنوان: Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
المؤلفون: Zuur CL; Department of Head and Neck Surgery, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. cl.zuur@vumc.nl, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR
المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2008 Oct; Vol. 89 (1), pp. 38-43. Date of Electronic Publication: 2008 Aug 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0167-8140 (Print) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier Scientific Publishers
Original Publication: Amsterdam : Elsevier Science Publishers, c1983-
مواضيع طبية MeSH: Cisplatin/*adverse effects , Head and Neck Neoplasms/*drug therapy , Head and Neck Neoplasms/*radiotherapy , Hearing Loss/*chemically induced , Radiotherapy/*adverse effects, Audiometry ; Combined Modality Therapy ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Risk Factors ; Statistics, Nonparametric
مستخلص: Background and Purpose: Cisplatin-based chemo-irradiation (CRT) is increasingly used for head and neck squamous cell carcinoma (HNSCC). We aimed to assess hearing deterioration due to low-dose cisplatin chemoradiation and to compare the observed hearing loss with hearing loss in our previously described high-dose cisplatin CRT cohort.
Materials and Methods: A prospective analysis of hearing thresholds at low and (ultra)-high frequencies obtained before and after treatment in 60 patients. Patients received low-dose cisplatin (6mg/m(2), daily infusions, 20-25 days) with concomitant accelerated radiotherapy (70Gy).
Results: Audiometry up to 16kHz was performed before therapy and 31 days (median) post-treatment. The total incidence of ototoxicity in CTCAEv3.0 was 31% in audiograms up to 8kHz, and 5% of ears tested qualified for HAs due to treatment. The mean hearing loss at speech frequencies was 2.6dB (SD 5.7) and 2.3dB (SD 9.2) at PTA 1-2-4kHz air-conduction and bone-conduction, respectively. The mean hearing loss at ultra-high frequencies (PTA AC 8-10-12.5kHz) was 9.0dB (SD 8.1). Low-dose cisplatin CRT caused less acute hearing loss (CTCAE 31%), compared to high-dose cisplatin CRT (CTCAE 78%).
Conclusions: Low-dose cisplatin chemo-irradiation for HNSCC is a relatively safe treatment protocol with respect to ototoxicity.
التعليقات: Comment in: Radiother Oncol. 2009 Feb;90(2):282, author reply 282-3. (PMID: 19042049)
المشرفين على المادة: Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20080819 Date Completed: 20090210 Latest Revision: 20131121
رمز التحديث: 20240628
DOI: 10.1016/j.radonc.2008.06.003
PMID: 18706728
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا